



This analysis examines the new, typically innovative pharmaceutical technologies that have been submitted but do not yet make the final decision by the National Health Insurance Fund of Hungary (NHIFA) and Ministry of Human Capacities (MoHC). This special edition has been updated with the 7 month event since the [previous report](#). The previous marked in red are also represented to make the changes clear visible. The analysis focuses only on the technologies that passed the standard 90 days period and bases on the data published by the NHIFA on July 27, 2018. The validity of published data has not been investigated by Healthware.

Number of the ongoing submission procedures by reimbursement category (brands)²




Almost all new products (~83%) (~90%) targeted a 100% reimbursement category.


In 38 (28) SKUs the exact Indications are unknown.



Average procedure length by reimbursement category (days)²




Average procedure length by ATC main groups (days)²




Number of the ongoing submission procedures by ATC5 codes²

ATC5	Name	Brands	SKUs
L01XC	Monoclonal antibodies	9	31
L01XE	Protein kinase inhibitors	10	20
L04AC	Interleukin inhibitors	5	10
C09DX	Angiotensin II antagonists, other combinations	2	8
L04AA	Selective immunosuppressants	5	8
L01XX	Other antineoplastic agents	4	7
B02BD	Blood coagulation factors	2	6
N05AX	Other antipsychotics	1	4
L01BB	Purine analogues	1	3
L01BC	Pyrimidine analogues	2	3
L04AB	Tumor necrosis factor alpha (TNS- α) inhibitors	3	4
L04AX	Other immunosuppressants	2	3
R03DX	Other systemic drugs for obstructive airway diseases	3	3
B01AC	Platelet aggregation inhibitors excl. heparin	1	2
B03AC	Iron, parenteral preparations	1	2
C10AX	Other lipid modifying agents	2	2
J05AP	Antivirals for treatment of HCV infections	2	2
L01CD	Taxanes	2	2
N03AX	Other antiepileptics	1	2
N07BA	Drug used in nicotine dependence	1	2
S01LA	Antineovascularisation agents	2	2
A04AA	Serotonin (5HT3) antagonists	1	1
C01DA	Organic nitrates	1	1
C02KX	Antihypertensives for pulmonary arterial hypertension	1	1
G03GA	Gonadotropins	1	1
H05AA	Parathyroid hormones and analogues	1	1
H05BX	Other anti-parathyroid agents	1	1
J01XA	Glycopeptide antibacterials	1	1
J05A	Direct acting antivirals	1	1
J05AR	Antivirals for treatment of HIV infections, combinations	1	1
J06BA	Immunoglobulins, normal human	1	1
L02AB	Progestogens	1	1
L02BX	Other hormone antagonists and related agents	1	1
L03AB	Interferons	1	1
M03AX	Other muscle relaxants, peripherally acting agents	1	1
M09AX	Other drugs for disorders of the musculo-skeletal system	1	1
N01AH	Opioid amesthetics	1	1
R03AL	Adrenergics in combination with anticholinergics incl. Triple combinations with corticosteroids	1	1
S01XA	Other ophthalmologicals	1	1
V04CJ	Test for thyroidea function	1	1
V06D	Other nutrients	1	1
	n.a.	1	1
Total		82	147

Top 3 applicants by the number of brands and SKUs²



Top 3 ATC main group by the number of brands and SKUs²




During the NHIFA co-ordinated period, the financing structure for the technology will be determined on the basis of submitted and agreed HTA, BIA and medical considerations. The final decision is taken by a Committee coordinated by the Ministry. Actual timelines of ongoing procedures are the followings:

- 75% are waiting for the final decision more than 90 days.
- NHIFA made a positive preliminary decision on 63,4% of the submissions.
- The average procedure time of the analyzed products is 560 days (min-max: 224 and 1127 days).
- The average procedure time of NHIFA is 262 days (min-max: 21 and 958 days).
- The average procedure time of MoHC is 324 days (min-max: 190 and 758 days).

The most frequent indications are neoplastic diseases as it was found at the [previous report](#), too.

In April, political election was held in Hungary. Positive decision's publications of ongoing procedures at the Bulletin is still awaited. Meanwhile, many new technologies have been waiting for ministerial positive decision, while the release time of previous products has continued to grow. The publication of this products is tasks of the new minister of MoHC (Miklós Kásler), its timing is currently highly questionable.

With further questions, [please contact us!](#)



¹ NHIFA: National Health Insurance Fund of Hungary
² Healthware analysis based on NHIFA data
³ Standard official process period of NHIFA